Are KRAS mutations druggable?

Marina Garassino (Italy)

Source: New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine
Number: 2

Slide presentationPDF journal article, handout or slidesWebcast

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
Marina Garassino (Italy). Are KRAS mutations druggable?. New biomarkers, molecules and therapeutic sequences for non small cell lung carcinoma in the era of precision medicine

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you: